LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

22.1 -4.16

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

21.28

Максимум

22.52

Ключови измерители
By Trading Economics
Приходи	7M -102M
Продажби	996K 8.5M
Марж на печалбата	-1,208.257
Служители	509
EBITDA	17M -97M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+69.55% upside

Дивиденти
By Dow Jones
Следващи печалби	11.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	531M 2.5B
Предишно отваряне	26.26
Предишно затваряне	22.1

Настроения в новините

By Acuity

49%

51%

180 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.225 / 20.17 Подкрепа & съпротива

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.11.2025 г., 21:06 ч. UTC

Значими двигатели на пазара

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7.11.2025 г., 22:36 ч. UTC

Печалби

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7.11.2025 г., 22:22 ч. UTC

Печалби

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Rev $2.95B >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Net $210M >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q EPS $9.89 >CSU.T

7.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

7.11.2025 г., 20:59 ч. UTC

Печалби

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7.11.2025 г., 20:26 ч. UTC

Пазарно говорене

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7.11.2025 г., 20:22 ч. UTC

Печалби

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7.11.2025 г., 20:04 ч. UTC

Пазарно говорене

Oil Futures Close Choppy Week With Losses -- Market Talk

7.11.2025 г., 19:34 ч. UTC

Пазарно говорене

Gold Posts Small Gain for Week -- Market Talk

7.11.2025 г., 19:31 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7.11.2025 г., 19:17 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7.11.2025 г., 19:09 ч. UTC

Печалби

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7.11.2025 г., 19:08 ч. UTC

Печалби

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7.11.2025 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7.11.2025 г., 17:27 ч. UTC

Пазарно говорене

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

7.11.2025 г., 17:17 ч. UTC

Придобивния, сливания и поглъщания

Satair Expects to Complete Purchase in Early 2026

7.11.2025 г., 17:17 ч. UTC

Придобивния, сливания и поглъщания

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7.11.2025 г., 17:15 ч. UTC

Придобивния, сливания и поглъщания

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7.11.2025 г., 17:09 ч. UTC

Пазарно говорене

PENN Is Falling Further Behind Competitors -- Market Talk

7.11.2025 г., 16:49 ч. UTC

Пазарно говорене

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7.11.2025 г., 16:24 ч. UTC

Пазарно говорене

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7.11.2025 г., 16:17 ч. UTC

Пазарно говорене

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

69.55% нагоре

12-месечна прогноза

Среден 39.25 USD 69.55%

Висок 80 USD

Нисък 21 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

180 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.